Robotic pill company Rani Therapeutics (Nasdaq:RANI) has begun developing RT-111, a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s (NYSE:JNJ) Stelara (ustekinumab).
The company anticipates that RT-111 could potentially treat psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis.
The FDA first approved Stelara in 2009 for psoriasis.
Stelara is available in intravenous and subcutaneous doses. It is most commonly administered subcutaneously.
Get the full story at our sister site, Pharmaceutical Processing World.